title: Liposome-encapsulated hemoglobin attenuates cardiac dysfunction and sympathetic activity during hypohemoglobinemic shock.
abstract: The use of liposome-encapsulated hemoglobin (LHb), which is a cellular Hb, has been demonstrated to be beneficial in the treatment of hypohemoglobinemic shock. As a molecule of appropriate size (220 nm) that can carry oxygen, LHb may ameliorate cardiac dysfunction during lethal hemodilation. The purpose of this study was to determine the efficacy of LHb transfusion in relieving cardiovascular dysfunction in a rat model of lethal progressive hemodilution. Over the course of 150 min, rats were subjected to blood withdrawal (0.2 mL/min) and simultaneously transfused with LHb, washed rat red blood cells, or 5% albumin. Temporal changes in cardiac function, heart-type fatty acid-binding protein levels, plasma levels of catecholamines, heart rate variability, and hypoxia-inducible factor 1α expression were measured during lethal progressive hemodilution. More than 80% of the rats transfused with either LHb or washed rat red blood cells survived for 8 days. Liposome-encapsulated hemoglobin transfusion suppressed hypoxia-inducible factor 1α expression in the heart, maintained low levels of heart-type fatty acid-binding protein, and attenuated sympathetic nerve activity as reflected by changes in heart rate variability and plasma levels of epinephrine and norepinephrine. The results indicate that LHb attenuates cardiac dysfunction and sympathetic overactivity during lethal hemorrhage.
authors.affiliation: Departments of Surgery, Research Institute, National Defense Medical College Research Institute, Tokorozawa, Saitama, Japan.
authors.forename: Yashiro
authors.initials: Y
authors.lastname: Nogami
authors.forename: Bonpei
authors.initials: B
authors.lastname: Takase
authors.forename: Manabu
authors.initials: M
authors.lastname: Kinoshita
authors.forename: Satoshi
authors.initials: S
authors.lastname: Shono
authors.forename: Shinichi
authors.initials: S
authors.lastname: Kaneda
authors.forename: Yoshihiro
authors.initials: Y
authors.lastname: Tanaka
authors.forename: Satoko
authors.initials: S
authors.lastname: Kishimoto
authors.forename: Hidemi
authors.initials: H
authors.lastname: Hattori
authors.forename: Masayuki
authors.initials: M
authors.lastname: Ishihara
mesh_terms: D000140:Acidosis, Lactic / Q000517:prevention & control; D000818:Animals; D016913:Blood Component Transfusion; D002395:Catecholamines / Q000378:metabolism; D004195:Disease Models, Animal; D050556:Fatty Acid-Binding Proteins / Q000378:metabolism; D006331:Heart Diseases / Q000503:physiopathology / Q000517:prevention & control*; D006339:Heart Rate / Q000187:drug effects; D006438:Hemodilution / Q000379:methods; D006454:Hemoglobins / Q000008:administration & dosage* / Q000172:deficiency / Q000494:pharmacology; D051795:Hypoxia-Inducible Factor 1, alpha Subunit / Q000378:metabolism; D008081:Liposomes; D008297:Male; D051381:Rats; D017207:Rats, Sprague-Dawley; D012771:Shock, Hemorrhagic / Q000628:therapy*; D013318:Stroke Volume / Q000502:physiology; D015996:Survival Rate; D013564:Sympathetic Nervous System / Q000187:drug effects*
chemical_list: D002395:Catecholamines; D050556:Fatty Acid-Binding Proteins; D006454:Hemoglobins; D051795:Hypoxia-Inducible Factor 1, alpha Subunit; D008081:Liposomes